Pharmaceutical Cluster in Portugal | Deloitte Portugal | Life Sciences and Health Care has been added to your bookmarks.
Pharmaceutical Cluster in Portugal and Michael Porter Diamond Theory
Business case study
How can Portugal become a reference for the Pharmaceutical Cluster in Europe?
This research study puts forward 10 policies that, if implemented, could enable the Portuguese Pharmaceutical Cluster to further develop and ultimately become a major player in the Portuguese economy. In this study, several factors of the Portuguese economy are analyzed using the Michael Porter Diamond Theory of national advantages. Among the policies proposed is the development of a strategy that, on the one hand, will attract shared services between multinational pharmaceutical companies, and, on the other hand, will make Portugal a European reference for clinical trials. These policies, together with all the others proposed in this paper, could have a significant impact within the Portuguese Pharmaceutical Cluster and, consequently, make this Cluster become a powerful economic force within the Portuguese economy and improve patients’ well-being and quality of life.
About the author:
A Portuguese researcher who wishes to contribute to the economic growth and prosperity of his home country. He has been working in one of the largest pharmaceutical companies in the world (Novartis) for more than 9 years, having already worked in France, Germany and Switzerland. He has held various functions such as: Research and Development, Production, Project Management, Global Supply Chain and most recently Key Account Management. He was awarded a Master’s in Biological Engineering by Instituto Superior Técnico (Portugal) and completed his MBA in 2015 at the University of St. Gallen (Switzerland).